Celltrion, Inc.
068270
Classement en actions
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Prix de l'action
$146.63
Capitalisation boursière
$33.44B
Changement (1 jour)
-1.52%
Changement (1 an)
23.60%
Pays
KR
Échange Celltrion, Inc. (068270)
Catégorie
Healthcare
Bénéfices pour Celltrion, Inc. (068270)
Bénéfices en Jun 2026 TTM : $1.35B
Selon les derniers rapports financiers de Celltrion, Inc., les bénéfices actuels de l'entreprise sont de $1.35B. En 2024, l'entreprise a réalisé un bénéfice de $391.87M, une diminution par rapport à celui de 2023 qui était de $518.41M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Celltrion, Inc. de 2007 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $1.35B | 69.43% |
| 2025 | $798.62M | 103.80% |
| 2024 | $391.87M | -24.41% |
| 2023 | $518.41M | 4.47% |
| 2022 | $496.21M | -20.13% |
| 2021 | $621.28M | 2.64% |
| 2020 | $605.31M | 82.96% |
| 2019 | $330.83M | 22.13% |
| 2018 | $270.89M | -40.24% |
| 2017 | $453.27M | 138.31% |
| 2016 | $190.20M | 37.04% |
| 2015 | $138.79M | 1.86% |
| 2014 | $136.26M | 24.03% |
| 2013 | $109.86M | -37.65% |
| 2012 | $176.20M | 11.36% |
| 2011 | $158.22M | 61.51% |
| 2010 | $97.97M | 71.21% |
| 2009 | $57.22M | 319.20% |
| 2008 | $13.65M | 4,681.03% |
| 2007 | $285.51K | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | 289.84% |
US
|
|
| $-3.09B | -328.14% |
US
|
|
| $-4.02B | -396.82% |
AU
|
|
| $2.85B | 110.31% |
BE
|
|
| $1.95B | 44.16% |
NL
|
